Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space.
Tag Archive for: Novo Nordisk
A German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
Novo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials.